UK patients with moderately to severely active ulcerative colitis gain access to a range of biologic therapies on the NHS
15 December 2014 | By MSD
NICE says ‘yes’ to REMICADE® (infliximab), HUMIRA® (adalimumab) and SIMPONI® (golimumab) for adult patients with moderately to severely active ulcerative colitis...